anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Risperidone
Trial phase: Phase 4
ATC code: N05AX08
SMILES: Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 79
Group description: Risperidone 25 milligram (mg) was administered as intramuscular injection (injection of a substance into a muscle) every 2 weeks up to 6 months
Eligibility criteria:
Inclusion Criteria:

Symptomatically stable participants defined as a) participants with treatment on outpatient and inpatient basis for at least 4 weeks before entering the study, and b) Positive and Negative Syndrome Scale (PANSS) Positive Subscale Score less than or equal to (<= ) 3 (1-7), including conceptual disorganization, suspicion, hallucinatory conduct and delirium (state of violent mental agitation)
Participants under antipsychotic treatment with extrapyramidal symptoms, persistent negative symptoms or lack of adherence defined as irregular administration of medication in the last 2 weeks
Participants who have given their informed consent in writing, or at least, by their family member or personal representative

Exclusion Criteria:

Participants taking first antipsychotic treatment in his/her life
Participants with any other psychotic disorder different to the previously mentioned in the inclusion criteria
Pregnant or nursing women
History of neuroleptic malignant syndrome (potentially fatal syndrome associated primarily with the use of antipsychotic drugs and clinical features include diffuse muscle rigidity, tremor, high fever) or current symptoms of tardive dyskinesia (a neurological disorder characterized by involuntary movements of the face and jaw)
Participants with known intolerance or lack of response to risperidone
Intervention: Stribild
Trial phase: Phase 4
SMILES: CC(C)OC(=O)OCOP(=O)(COC(C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C.CC(C)c1nc(CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(CCC(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1.COc1cc2c(cc1Cc1cccc(Cl)c1F)c(=O)c(C(=O)O)cn2C(CO)C(C)C.Nc1nc(=O)n(C2CSC(CO)O2)cc1F.O=C(O)C=CC(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 100
Group description: Coformulated Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg) taken for 28 days, within 72 hours of a possible sexual exposure to HIV

Coformulated Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg)
Eligibility criteria:
Inclusion Criteria:

> Age of 18 at time of first visit.
HIV uninfected on the basis of a negative HIV Rapid Test
Willing and able to provide written informed consent.
Willing and able to provide adequate locator information.
Willing and able to return to all study visits.
Willing to participate in all study procedures.
Biologic women of childbearing potential: Willing to use contraception for as long as they are on study medication plus 7 days after.
Possible sexual exposure to HIV-1, recent enough to permit receiving the first dose of study medication within 72 hours from the end of the exposure.

possible exposure could include:

Unprotected anal, vaginal, oral, or mucosal (e.g. conjunctival) exposure to ejaculate from a partner who is HIV-1 infected or high risk for HIV infection and of unknown HIV-1 serostatus (may include protected sexual exposure with condom failure, breakage or slippage); or
Unprotected penile exposure to cervicovaginal secretions or anorectal secretions from a partner who is HIV-1 infected or high risk for HIV infection and of unknown HIV-1 serostatus (may include protected sexual exposure with condom failure, breakage or slippage)

Exclusion Criteria:

An active psychiatric illness or active drug or alcohol abuse that, in the opinion of the investigator, could prevent compliance with study procedures.
Pregnancy and/or Breastfeeding.
Biologic women who are actively trying to become pregnant.
Acute or Chronic Hepatitis B infection, by history
Acute or Chronic Renal Disease, by history
Creatinine Clearance at or below 70mL/min (Cockcroft-Gault equation, Actual Weight)
Known intolerance or allergy to tenofovir DF, emtricitabine, elvitegravir or cobicistat

Currently taking or plans to take prohibited medication while enrolled in the study.

Prohibited Medications*

Propulsid (Cisapride)
UroXatral (Alfuzosin)
Dihydroergotamine
Ergotamine
Methylergonovine
St John's Wort (Hypericum perforatum)
Altocor, Altoprev, Mevacor (Lovastatin)
Zocor (Simvastatin)
Orap (Pimozide)
Rifadin, Rimactane (Rifampin)
Viagra (Sildenafil when dosed as REVATIO)
Halcion (Triazolam)
Versed (Midazolam) (when administered orally)
Antiretroviral medications used to treat or prevent HIV infection.
Intervention: Amitriptyline
Trial phase: Phase 2
ATC code: N06AA09 | N06CA01
SMILES: CN(C)CCC=C1c2ccccc2CCc2ccccc21
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 24
Group description: The Immediate group will begin study drug immediately after enrollment. Immediate Drug participants will be started on one 10 mg capsule each evening. The dosage will be adjusted upwards to 25 mg daily for Week 2 to a maximum of 50 mg daily by Week 3.
Eligibility criteria:
Inclusion Criteria:

Acute mild TBI (Glasgow Coma Scale of 13-15 on emergency department evaluation, any period of loss of consciousness (LOC) < than 30 minutes, alteration of consciousness or post-traumatic amnesia (not to exceed 24 hours)
Ability to give consent
Ages 18-60
Access to a telephone
Current headache (new headache or headache worse than prior to injury)

Exclusion Criteria:

Does not speak English
Diagnosed seizure disorder
Myocardial infarction in prior 6 months
Cardiac arrhythmia requiring medication treatment
Prolonged Q-T interval on electrocardiogram
Psychosis
Intoxication on hospital admission sufficient enough to cloud the diagnosis of mild TBI
Incarceration or homelessness
Allergy to amitriptyline
Current treatment with amitriptyline or other tricyclic antidepressant
Currently taking any medication not recommended for use with amitriptyline due to the potential for Q-T interval prolongation. Examples of this include: Class I, I-A or II antiarrhythmics, TCA's, MAOI's, selected fluoroquinolones (gatifloxacin, moxifloxacin), selected antipsychotic medications (haloperidol, risperidone, quetiapine), selected antiretroviral medications, cisapride, chloroquine, chlorpromazine, prochlorperazine, promethazine, citalopram, fluoxetine, erythromycin, methadone
History of glaucoma
History of prostate disease or current urinary retention
Intervention: Amitriptyline
Trial phase: Phase 2
ATC code: N06AA09 | N06CA01
SMILES: CN(C)CCC=C1c2ccccc2CCc2ccccc21
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 26
Group description: The Delayed group will start the study drug at the Day 30 visit on one 10 mg capsule each evening to assess whether there is any cognitive impact of the medication (comparing to those who started immediately after enrollment. The dosage will be adjusted upwards to 25 mg daily for Week 2 to a maximum of 50 mg daily by Week 3.
Eligibility criteria:
Inclusion Criteria:

Acute mild TBI (Glasgow Coma Scale of 13-15 on emergency department evaluation, any period of loss of consciousness (LOC) < than 30 minutes, alteration of consciousness or post-traumatic amnesia (not to exceed 24 hours)
Ability to give consent
Ages 18-60
Access to a telephone
Current headache (new headache or headache worse than prior to injury)

Exclusion Criteria:

Does not speak English
Diagnosed seizure disorder
Myocardial infarction in prior 6 months
Cardiac arrhythmia requiring medication treatment
Prolonged Q-T interval on electrocardiogram
Psychosis
Intoxication on hospital admission sufficient enough to cloud the diagnosis of mild TBI
Incarceration or homelessness
Allergy to amitriptyline
Current treatment with amitriptyline or other tricyclic antidepressant
Currently taking any medication not recommended for use with amitriptyline due to the potential for Q-T interval prolongation. Examples of this include: Class I, I-A or II antiarrhythmics, TCA's, MAOI's, selected fluoroquinolones (gatifloxacin, moxifloxacin), selected antipsychotic medications (haloperidol, risperidone, quetiapine), selected antiretroviral medications, cisapride, chloroquine, chlorpromazine, prochlorperazine, promethazine, citalopram, fluoxetine, erythromycin, methadone
History of glaucoma
History of prostate disease or current urinary retention
Intervention: Ramipril
Trial phase: Not Applicable
ATC code: C09AA05 | C09BA05 | C09BB05 | C09BB07 | C09BX03 | C09BX05 | C10BX04 | C10BX06 | C10BX17 | C10BX18
SMILES: [H][C@@]12CCC[C@]1([H])N(C(=O)[C@H](C)N[C@@H](CCc1ccccc1)C(=O)OCC)[C@H](C(=O)O)C2
Sex: Male
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 2
Group description: The initial dose of ramipril will be 2.5 mg that will be started at visit 2, week zero of the study. The dose will be increased to 5 mg during visit 3, 4 weeks into the study, for a total of 32 weeks.

Ramipril: Angiotensin Converting Enzyme Inhibitor
Eligibility criteria:
Inclusion Criteria:

Male partner of a couple presenting for infertility.
Moderate abnormalities of semen parameters (Mean sperm density <20 million, but ≥ 3 million/ml), and/or motility < 50%, and/or < 4% abnormal morphology on at least two separate occasions.
Age 18-45 years.
Normal renal function defined as Glomerular filtration rate > 90

Exclusion Criteria:

Patients that are currently taking thiazide, cyclosporin, lithium, and allopurinol or the use of these medications in the last 2 weeks.
The frequent use of NSAIDS (3 or more times a week).
Vasectomy reversal.
Regular use of tobacco products.
Mean white blood cell count >1 million/ml in the ejaculate.
Inability or unwillingness to participate in evaluations required by the study.
Potassium > 5.0.
Systolic blood pressure < 90 mmHg.
Currently use of ACEI
Intervention: OXYTOCIN
Trial phase: Phase 1 | Phase 2
ATC code: H01BB02
SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 27
Group description: Liquid intranasal oxytocin, 24 IU, administered once

Oxytocin: Liquid metered-dose nasal spray, 24 IU, administered once
Eligibility criteria:
Inclusion Criteria:

Males > 18 years of age with a primary (or co-principal) psychiatric diagnosis of social anxiety disorder (SAD), as defined by Diagnostic and Statistical Manual-IV (DSM-IV) criteria;
Current Liebowitz Social Anxiety Scale (LSAS) score > 60, which is a clinical threshold for SAD symptoms;
Comorbid present DSM-IV Major Depression, Dysthymia, Specific Phobia, or any of the other anxiety disorders as diagnosed by DSM-IV criteria will be permitted as long as SAD is primary (the disorder that is most distressing to the patient). Inclusion of patients with comorbidity will permit accrual of a more clinically relevant patient population;
Willingness to participate in and comply with the study procedures as indicated by signing the informed consent form.

Exclusion Criteria:

Subjects with a serious medical illness for which hospitalization may be likely within the next three months;
Subjects with a current diagnosis of schizophrenia, psychotic disorders, bipolar disorder, mental disorder due to a medical condition or substance, substance abuse or dependence, as diagnosed by DSM-IV criteria;
Concurrent use of other psychotropic medications is excluded, except for antidepressants that have been taken at a stable dose for at least 2 weeks;
Active suicidal or homicidal ideation or suicide attempts within the past six months requiring hospitalization;
Subjects with significant nasal pathology (atrophic rhinitis, recurrent nose bleeds, or history of hypophysectomy);
Smokers who smoke more than 15 cigarettes per day;
Those who smoke cigarettes or have caffeine or alcohol within 24 hours of the study visit.
Intervention: Naltrexone
Trial phase: Phase 3
ATC code: A08AA62 | N02AA56 | N07BB04
SMILES: [H][C@@]12Oc3c(O)ccc4c3[C@@]13CCN(CC1CC1)[C@]([H])(C4)[C@]3(O)CCC2=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 23
Group description: an initial 50 mg oral dose of naltrexone prior to hospital discharge plus a 30-day prescription for oral naltrexone

Naltrexone: Naltexone was chosen for this study because naltrexone is the only medication available in both oral daily and injectable monthly formulations, which will allow the study to examine issues around medication adherence.
Eligibility criteria:
Inclusion Criteria:

18 years or older
diagnostic criteria for alcohol dependence or abuse
women of childbearing potential who have a negative screening urine pregnancy test and are willing to use reliable birth control methods throughout the duration of the study

Exclusion Criteria:

active or recently active (less than 1 year) opioid dependence or daily use of opioid analgesics
acute hepatitis or liver failure
pregnancy
women who are currently breastfeeding
active suicidality
inability to provide written informed consent as determined by study comprehension questions
Intervention: Naltrexone
Trial phase: Phase 3
ATC code: A08AA62 | N02AA56 | N07BB04
SMILES: [H][C@@]12Oc3c(O)ccc4c3[C@@]13CCN(CC1CC1)[C@]([H])(C4)[C@]3(O)CCC2=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 22
Group description: a single 380 mg intramuscular injection of naltrexone (duration of action = 30 days)prior to hospital discharge followed by a second injection one month later.

Naltrexone: Naltexone was chosen for this study because naltrexone is the only medication available in both oral daily and injectable monthly formulations, which will allow the study to examine issues around medication adherence.
Eligibility criteria:
Inclusion Criteria:

18 years or older
diagnostic criteria for alcohol dependence or abuse
women of childbearing potential who have a negative screening urine pregnancy test and are willing to use reliable birth control methods throughout the duration of the study

Exclusion Criteria:

active or recently active (less than 1 year) opioid dependence or daily use of opioid analgesics
acute hepatitis or liver failure
pregnancy
women who are currently breastfeeding
active suicidality
inability to provide written informed consent as determined by study comprehension questions
Intervention: Efficib
Trial phase: Phase 4
SMILES: CN(C)C(=N)N=C(N)N.Cl.NC(CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F.O=P(O)(O)O
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 12
Group description: 50 mg/1000 mg BID

Sitagliptin-Metformin: Experimental -DPP-4 inhibitor- oral medication
Eligibility criteria:
Inclusion Criteria:

Females 18 years to 42 years of age who experienced gestational diabetes mellitus (GDM) during recent (within 12 months) pregnancy with prediabetic hyperglycemia determined by an oral glucose tolerance test (OGTT) with 75 g glucose postpartum. Study subjects will be inclusive of prior GDM women with impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or both (IFG/IGT) postpartum.
Written consent for participation in the study

Exclusion Criteria:

Cholestasis during the past pregnancy
Any hepatic diseases in the past (viral hepatitis, toxic hepatic damage, jaundice of unknown etiology)
Serum aspartate transaminase (AST) and/or alanine aminotransferase (ALT) level exceeding more than twice normal lab values
Presence of hypersensitivity to sitagliptin or other DPP-4 inhibitor
Current use of metformin, thiazolidinediones, GLP-1 receptor agonists, DPP-4 inhibitors, or weight loss medications (prescription or over the counter [OTC])
Prior use of medication to treat diabetes except gestational diabetes
Use of drugs known to exacerbate glucose tolerance
History of diabetes or prior use of medications to treat diabetes except GDM
Creatinine clearance less than 60 ml/min
Pregnancy planned during the coming two years
Currently lactating
Patient not willing to use adequate contraception during study period (unless sterilized)
Intervention: Montelukast
Trial phase: Phase 3
ATC code: R03DC03 | R03DC53
SMILES: CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 216
Group description: Participants receive montelukast 5 mg for 7 days, regardless of sequence.
Eligibility criteria:
Inclusion Criteria:

Weight: ≥ 25 kg
Height: ≥ 125 cm
Able to record symptoms in a diary
Has had allergic rhinitis symptoms [Japanese Cedar (JC) pollinosis]
Tested positive for JC pollen specific immunoglobulin E (IgE) antibody assay

Exclusion Criteria:

Has nasal findings that would interfere with evaluating nasal congestion symptoms
Past or present medical history of bronchial asthma
Medical history of allergies except allergic rhinitis and has possibility of dramatically worsening of these symptoms induced by JC pollen exposure
Intervention: Fondaparinux
Trial phase: Phase 3
ATC code: B01AX05
SMILES: CO[C@H]1O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]2O[C@@H](C(=O)O)[C@@H](O[C@H]3O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]4O[C@H](C(=O)O)[C@@H](O[C@H]5O[C@H](COS(=O)(=O)O)[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)O)[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)O)[C@H]3NS(=O)(=O)O)[C@H](O)[C@H]2OS(=O)(=O)O)[C@H](O)[C@H]1NS(=O)(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Fondaparinux subcutaneously administered at a dose of 1.5mg once daily for 14 days.

Fondaparinux (20 mL/min ≤ CLCR < 30mL/min)
Eligibility criteria:
Inclusion Criteria:

Patients with SRI or MiRI undergoing orthopedic surgery of the lower limbs

Exclusion Criteria:

Patients who are on hemodialysis or are scheduled to undergo hemodialysis during the study period
Patients who are at a significantly high risk for bleeding or thromboembolism
Patients who are receiving another antithrombotic therapy and are unable to suspend the therapy
Patients who have evidence of hepatic function test abnormalities
Intervention: Edoxaban Tosylate
Trial phase: Phase 3
SMILES: CN1CCc2nc(C(=O)NC3CC(C(=O)N(C)C)CCC3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1.Cc1ccc(S(=O)(=O)O)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 50
Group description: Severe Renal Impairment DU-176b was orally administered at a dose of 15 mg once daily for 12 weeks.

DU-176b 15mg: oral DU-176b 15mg once daily
Eligibility criteria:
Inclusion Criteria:

Patients with NVAF and SRI, or patients with NVAF and Normal/MiRI.

Exclusion Criteria:

Patients who are on hemodialysis or patients who may start hemodialysis before the follow-up assessment
Patients who are at a significantly high risk for bleeding
Patients who are receiving treatment with any anticoagulant drugs excluding warfarin, rivaroxaban, and dabigatran
Patients who have evidence of hepatic function test abnormalities
Intervention: Edoxaban Tosylate
Trial phase: Phase 3
SMILES: CN1CCc2nc(C(=O)NC3CC(C(=O)N(C)C)CCC3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1.Cc1ccc(S(=O)(=O)O)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 21
Group description: Normal or Mild Renal Impairment DU-176b was orally administered at a dose of 60 mg once daily for 12 weeks in subjects who had none of the dose adjustment factors. DU-176b was orally administered at a dose of 30 mg once daily for 12 weeks to subjects who had any of the dose adjustment factors, irrespective of the number of dose adjustment factors.

DU-176b 60mg: oral DU-176b 60mg once daily
Eligibility criteria:
Inclusion Criteria:

Patients with NVAF and SRI, or patients with NVAF and Normal/MiRI.

Exclusion Criteria:

Patients who are on hemodialysis or patients who may start hemodialysis before the follow-up assessment
Patients who are at a significantly high risk for bleeding
Patients who are receiving treatment with any anticoagulant drugs excluding warfarin, rivaroxaban, and dabigatran
Patients who have evidence of hepatic function test abnormalities
Intervention: Nicotine
Trial phase: Phase 2
ATC code: N07BA01
SMILES: CN1CCCC1c1cccnc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 31
Group description: Patients do not receive activated Marrow Infiltrating Lymphocytes (aMIL)

No aMIL: On day 0, patients will receive auto transplant followed by Tadalafil. At day 60, patients will receive Lenalidomide.
Eligibility criteria:
Inclusion Criteria:

Age 18 - 80 years old;
Patients with active myeloma requiring systemic treatment;
Newly diagnosed patients. Relapsed myeloma patients that have not previously had a transplant;
Meeting criteria for high-risk disease;
Measurable serum and/or urine M-protein from prior to induction therapy documented and available. A positive serum free lite assay is acceptable;
Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2 (see Appendix C).
Meet all institutional requirements for autologous stem cell transplantation;
The patient must be able to comprehend and have signed the informed consent;
Patients must have had > than PR after last therapy.

Exclusion Criteria:

Diagnosis of any of the following cancers:

POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein [M-protein] and skin changes);
Non-secretory myeloma (no measurable protein on Serum Free Lite Assay);
Plasma cell leukemia;
Diagnosis of amyloidosis;
Failed to achieve at least a partial response (PR) to latest therapy;
Previous hematopoietic stem cell transplantation;Patients can have had prior relapsed disease as long as they have never been previously transplanted;
Known history of HIV infection;
Use of corticosteroids (glucocorticoids) within 21 days of bone marrow collection;
Use of any myeloma-specific therapy within 21 days of bone marrow collection;
Infection requiring treatment with antibiotics, antifungal, or antiviral agents within seven days of registration;
Participation in any clinical trial within 28 days of registration on this trial, which involved an investigational drug or device;
History of malignancy other than multiple myeloma within five years of registration, except adequately treated basal or squamous cell skin cancer;
Active autoimmune disease (e.g., rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosis) requiring active systemic treatment. Hypothyroidism without evidence of Grave's disease or Hashimoto's thyroiditis is permitted.
Human T-lymphotropic virus (HTLV) 1 or 2 positive;
Known hypersensitivity to Prevnar or any of its components;
Contraindication to phosphodiesterase-5 inhibitors (e.g. currently on nitrates).
Intervention: Ondansetron
Trial phase: Not Applicable
ATC code: A04AA01
SMILES: Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 502
Group description: Patients given ondansetron by ED provider decision or by triage nurse. This is an observational cohort only.

Oxycodone: Subjects given either oxycodone 5mg or hydrocodone/acetaminophen 5mg/500 mg by ED provider decision or by triage nurse randomization.

Hydrocodone: Subjects given either oxycodone 5mg or hydrocodone/acetaminophen 5mg/500 mg by ED provider decision or by triage nurse randomization.

Ondansetron: Subjects given ondansetron for reported nausea or vomiting. Treatment determined either by triage nursing protocol or by provider discretion. Observational intervention only.
Eligibility criteria:
Inclusion Criteria:

self-reported pain or nausea identified by the initial nursing assessment

Exclusion Criteria:

unable to speak English,
< 18 y.o.,
previously diagnosed with chronic pain or cyclic vomiting